Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US EPA approves Byotrol24 as long-lasting virucide

24 May 2023 15:14

RNS Number : 5499A
Byotrol PLC
24 May 2023
 

 

 

 

 

Byotrol Plc

 

("Byotrol" or the "Company")

 

EPA approval for

long-lasting performance against viruses

 

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, is pleased to announce that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. 

 

The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). 

The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.

 David Traynor, Executive Director, Byotrol plc comments:

 "This is fantastic news for Byotrol and confirms the excellence of our US surface sanitizers. 

Customers and consumers are now as concerned about protecting against viruses as well as bacteria. This new approval means we can now make specific long-lasting efficacy claims against viruses, which should in turn significantly increase the commercial potential of our US formulations."

 

 

For further information contact:

 

Byotrol Plc

David Traynor, Executive Director

Dr Trevor Francis, Non- Executive Chairman

+44 (0)1925 742 000

Vivan Pinto, Chief Executive Officer

Chris Sedwell, Chief Financial Officer

 

finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/George Dollemore - Corporate Finance

Nigel Birks/Harriet Ward - ECM

Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

byotrol@flagstaffcomms.com

 

 

 

 

 

This announcement is released by Byotrol Plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, go to byotrol.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUSASROUUVUAR
Date   Source Headline
6th Apr 202010:56 amRNSHolding(s) in Company
2nd Apr 202011:05 amRNSSecond Price Monitoring Extn
2nd Apr 202011:00 amRNSPrice Monitoring Extension
24th Mar 20209:05 amRNSSecond Price Monitoring Extn
24th Mar 20209:00 amRNSPrice Monitoring Extension
23rd Mar 20207:01 amRNSTrading Update
23rd Mar 20207:00 amRNSLicence and Product Supply Agreement with Tristel
16th Mar 20204:43 pmRNSSecond Price Monitoring Extn
16th Mar 20204:38 pmRNSPrice Monitoring Extension
13th Mar 20202:05 pmRNSSecond Price Monitoring Extn
13th Mar 20202:00 pmRNSPrice Monitoring Extension
28th Feb 20204:41 pmRNSSecond Price Monitoring Extn
28th Feb 20204:36 pmRNSPrice Monitoring Extension
28th Feb 20204:15 pmRNSHolding(s) in Company
30th Jan 20205:00 pmRNSDirector/PDMR Shareholding
30th Jan 20208:00 amRNSAcceleration of earn-out relating to Medimark
19th Dec 20197:00 amRNSInterim Results
14th Nov 201912:30 pmRNSResult of AGM
13th Nov 20197:00 amRNSHolding(s) in Company
8th Nov 20192:54 pmRNSHolding(s) in Company
11th Oct 20193:00 pmRNSRestoration - Byotrol Plc
11th Oct 20193:00 pmRNSPosting of Accounts, Notice of AGM and Restoration
1st Oct 20193:50 pmRNSHolding(s) in Company
1st Oct 20197:30 amRNSSuspension - BYOTROL PLC
30th Sep 201912:01 pmRNSPublication of accounts and temporary suspension
30th Sep 201912:00 pmRNSUnaudited Preliminary Results to 31 March 2019
25th Sep 20197:00 amRNSNotice of Results
3rd Sep 20199:08 amRNSNotice of Results
28th May 20197:00 amRNSAppointment of CFO & Award of Options
9th May 20197:00 amRNSTrading Update
15th Apr 201911:58 amRNSHolding(s) in Company
28th Feb 20197:00 amRNSEPA Approval and Target Roll-Out
31st Jan 20199:14 amRNSHolding(s) in Company
29th Jan 20197:00 amRNSAppointment of New Director & Award of Options
31st Dec 20187:00 amRNSGrant of Options
21st Dec 20181:41 pmRNSHolding(s) in Company
21st Dec 20181:41 pmRNSHolding(s) in Company
20th Dec 201812:07 pmRNSDirector Dealings
18th Dec 20187:00 amRNSInterim Results
14th Nov 201810:35 amRNSHolding(s) in Company
13th Nov 20184:00 pmRNSHolding(s) in Company
13th Nov 201811:20 amRNSDirector/PDMR Shareholding
12th Nov 20185:05 pmRNSHolding(s) in Company
21st Sep 20184:00 pmRNSResult of AGM
4th Sep 201811:15 amRNSPosting of Annual Report and Notice of AGM
3rd Sep 20184:48 pmRNSHolding(s) in Company
3rd Sep 20184:12 pmRNSHolding(s) in Company
24th Aug 201812:01 pmRNSDirector Dealing
24th Aug 20187:00 amRNSDirector Dealing
23rd Aug 201811:31 amRNSAcquisition of Medimark Scientific Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.